24 September 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Investor Presentation via Engage Investor

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces that the Company's Chairman Stephen West alongside Edward Painter and Sridhar Vempati, Chairman and Chief Strategy Officer respectively of A2A Pharmaceuticals, Inc. ("A2A Pharma") will host a live interactive presentation on the Engage Investor platform on Monday, 29 September 2025 at 4pm BST.

The objective of the presentation is to provide investors with an update relating to the proposed acquisition of Coiled Therapeutics, Inc. and its AO-252 clinical stage program from A2A Pharma.

All current shareholders and interested investors are invited to join and investors are encouraged to pre-submit questions via the Engage Investor platform. Investors can also submit questions at any time during the live presentation.

Investors can sign up to Engage Investor at no cost and follow Roquefort Therapeutics from their personalised investor hub.

Register interest in this event here:

https://engageinvestor.news/ROQ_IP_0925

ENDS

Enquiries:

LEI: ‎254900P4SISIWOR9RH34

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter)